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Type 1 diabetes mellitusAbstract Background: The major histocompatibility complex (MHC) genes have been implicated
as the major genetic component in the predisposition to type 1 diabetes mellitus (T1DM). Other loci
outside the MHC had also been reported to contribute in the susceptibility of T1DM. The aim of
this study was to examine the role of some variants of polymorphic sites in some genes associated
with T1DM in a sample of Egyptian children.
Patients and methods: 60 patients with T1DM from the diabetes clinic at Alexandria University
Children’s Hospital, and 60 healthy individuals were enrolled in this study. Genomic DNA was
extracted using isopropanol precipitation method. Interleukin 18 (IL-18), interleukin 10 (IL-10),
vitamin D receptor (VDR), protein tyrosine phosphatase non-receptor type 22 (PTPN22) and cyto-
toxic T-lymphocyte antigen-4 (CTLA-4) were genotyped.
Results: The ﬁndings obtained from logistic regression analysis suggest that the IL-18 single
nucleotide polymorphisms SNP-137 G>C (rs#187238), the VDR Fok1 SNP T>A (rs#2228570)
and the SNP-1123 C>G (rs#2488457) in PTPN22 gene showed a signiﬁcant difference between
patients and controls (P= 0.026, 0.030, and 0.003, respectively). The genotype distributions of
PTPN22 SNP-1858, CTLA-4 SNP 49, IL-10 SNP-819, IL-18 SNP-607, and VDR BsmI SNP
G>A did not show any signiﬁcant difference.
Conclusion: The IL-18 SNP-137 G>C (rs#187238), VDR SNP-Fok1 T>A (rs#2228570), and
the SNP-1123 C>G (rs#2488457) in PTPN22 gene may have an effect on the occurrence of
Figure 1 The type 1 diabetes risk ge
dots are the loci identiﬁed in linkage
266 A.A. El-Kafoury et al.T1DM in Egyptian children. Further large-scale, population-based, case-control studies are
needed.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Type 1 diabetes mellitus (T1DM) is a common, chronic
metabolic disorder characterized by hyperglycemia as a cardi-
nal biochemical feature and disturbances of carbohydrate, fat
and protein metabolism, associated with absolute or relative
deﬁciencies in insulin secretion and/or action [1]. This is
usually due to autoimmune destruction of the pancreatic beta
cells (type 1A) [2].
The incidence varies from more than 40 per 100,000 chil-
dren in Finland to less than two per 100,000 in Japan. A rise
in the numbers of children and adolescents with T1DM has
been observed since the mid-1950s, both in high- as well as
low risk countries. The current global prevalence rate is
0.025% for children under 15 years of age, with the average
increase in the annual incidence rate for this age group being
3% [3,4].
T1DM is a complex polygenic disorder and cannot be
classiﬁed strictly by dominant, recessive, or intermediate
inheritance, making identiﬁcation of disease susceptibility or
resistance genes difﬁcult [5,6].
The major histocompatibility complex (MHC) genes
have been implicated as the major genetic component in the
predisposition to T1DM but other genes are likely to be
involved such as Interleukin-10 (IL-10), Interleukin-18
(IL-18), cytotoxic T-lymphocyte antigen-4 gene (CTLA-4),
Toll-like receptors 2 (TLR2), insulin gene (INS), protein tyro-
sine phosphatase non-receptor 22 (PTPN22), interleukin 2
receptor alpha (IL2RA/CD25), glutamate decarboxylase 2
(GAD2), vitamin D-receptor (VDR) gene and others. These loci
have all been proved important in the pathogenesis ofne loci paced over the genome. St
studies [10]. The red stars are geautoimmunity when globally considered, whereas the insulin
gene is a disease-speciﬁc T1DM predisposition locus [5,6].
At least 20 different chromosomal regions have been linked
to T1DM susceptibility in humans, using genome screening,
candidate gene testing and studies of human homologues of
mouse susceptibility genes [7].
Since 2001 a signiﬁcant number of genome-wide association
(GWA) studies have been reported. Data from The Interna-
tional Type 1 Diabetes Genetics Consortium (T1DGC),
collected through multiple GWA studies and large scale
meta-analyses, identiﬁed more than 40 loci that affect the
previously reported as regions associated with T1DM suscep-
tibility. Eighteen additional regions showed signiﬁcant associ-
ation with T1DM and several of them contain new candidate
genes of possible relevance to T1DM (IL19, IL20, GLIS3,
CD69 and IL27). Most of the listed genes mediate the immune
response, some exert their functions in the process of destruc-
tion of pancreatic b cells and some have a dual role [8].
Additional functional studies provided evidence of causality
of several genes within established loci, such as several
cytokines and their receptors, immunomodulatory molecule.
However, for the majority of associated regions the most likely
causal gene still needs to be identiﬁed [9].
The aim of this study was to examine the role of some vari-
ants of polymorphic sites in some genes associated with T1DM
in a sample of Egyptian children.
2. Patients and methods
A total of 60 patients with type 1 diabetes (25 male/35
female) from the Diabetes Clinic at Alexandria Universityars are the loci that have shown evidence of association to T1DM,
nes loci that were investigated on chromosomes.
Figure 2 1% agarose gel electrophoresis of DNA extracted from
whole blood samples of some subjects under study (lanes 1–5).
Lane (M) represents 100 bp DNA ladder.
M          1          2         3
305 bp
193 bp
Figure 3 2% agarose gel electrophoresis for allele speciﬁc PCR
for Il-18 SNP-607 C>A (rs#1946518). M: 100 bp DNA ladder
from GeneDireX. Lane 1: PCR product upon using control
forward primer, lanes 2 and 3: PCR products, represent hetero-
zygous upon using allele speciﬁc C primer and allele speciﬁc A
primer respectively, lane 2: PCR products represent homozygous
upon using allele speciﬁc C primer and lane 3 will be empty, lane 3:
PCR products represent homozygous upon using allele speciﬁc A
primer and lane 2 will be empty.
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(33 male/27 female) were enrolled in this study. Patients were
diagnosed according to WHO criteria [11]. Demographic
details were obtained for all subjects; including age, sex,
duration of diabetes, ﬁrst-degree family history of diabetes.
Controls had no personal or ﬁrst-degree history of diabetes.
Blood sampling was carried out from September 2012 to
December 2012. One ml of venous blood sample was collected
in EDTA tubes from each individual (patient or healthy con-
trol) and was stored as whole blood at 20 C for subsequent
DNA isolation.
All chemicals used in this study were of molecular biology
analytical grade. Agarose was from peQ labs Co. PCR Master
Mix (GoTaq ready green Master Mix) was from Promega
Co. and Thermo Co. Restriction enzymes (FastDigest HhaI,
and FastDigest RsaI) were from New Engl and BioLabs Inc.
Gel loading dye and DNA ladder (Gene DireX 100 and 50 bp
ladder RTU ready to use) were from GeneDirex Co. Trizma-
base, EDTA and borate were from Winlab Co. Ethidium bro-Figure 4 2% agarose gel electrophoresis for (RFLP) PCR for V
GeneDireX. Lane 1: PCR product upon using lane 1 represents hom
FastDigest HhaI into 104 bp and 185 bp, lane 2 represents heterozygo
RsaI into 104 bp and 185 bp while A allele PCR products were still 29
Digest HhaI still into 290 bp.mide (EtBr) was from Biobasics Co. Isopropanol and ethanol
were from Fluka.
In this study, the following ﬁve genes were genotyped
(Fig. 1):
 PTPN22, [SNP1858 C>T (rs#2476601), SNP-1123 C>G
(rs#2488457) and SNP-2740 CPT (rs#1217412)].
 VDR [Fok1 SNP T>A (rs#2228570) and BsmI SNP-G>A
(rs#1544410)].
 IL-10 [SNP-1082 G>A (rs#1800896) and SNP-819 C>T
(rs#3021097].DR SNP G>A (rs#1544410). M: 100 bp DNA ladder from
ozygous GG genotype as the G allele PCR products cleaved by
us GA genotype as G allele PCR products cleaved by Fast Digest
0 bp, and lane 3 represents homozygous AA after cleaved by Fast
268 A.A. El-Kafoury et al. IL-18 [SNP-607 C>A (rs#1946518) and SNP-137 G>C
(rs#187238)].
 CTLA-4 [SNP-49 G>A (rs#231775)].
Genomic DNA was extracted using isopropanol precipita-
tion as described by Sambrook et al. [12]. A partial fragment
of the gene of interest containing the target SNP was retrieved
from the dbSNP (an online single nucleotide polymorphism
database). For allele speciﬁc PCR, four primers were designed,
control forward, common reverse and two allele speciﬁc
primers. The two allele speciﬁc primers for each SNP had
the same nucleotide sequence except for the last nucleotide at
the 30 prime end of the primer.
Twomolecular techniques were employed to amplify the tar-
get SNPs; allele speciﬁc PCR (Fig. 3) and Restriction Fragment
Length Polymorphism-PCR (RFLP-PCR) (Fig. 4). IL-18,
IL-10, and CTLA-4 antigen SNPs were genotyped using allele
speciﬁc PCR. PTPN22 andVit D receptor SNPswere genotyped
using both techniques.
Two restriction enzymes (RsaI and HhaI) were used in this
study. The isolated DNA from all patients and controls under
study was analyzed through agarose gel electrophoresis
(Fig. 2).3. Statistical analysis of data
Data were processed using SPSS package version 16. Descrip-
tive statistics including frequency, distribution, mean, and stan-
dard deviation (SD) were used to describe different clinical
characteristics. Univariate analyses including: t-test and Mann
Whitney test were used to test the signiﬁcance of results of quan-
titative variables and Chi-Square test was used to test for signif-
icance among categorized variables. Logistic regression was
used to obtain odds ratios for variables with signiﬁcant P-val-
ues. The conﬁdence interval (CI) at 95% was used to describe
the amount of uncertainty associated with the samples. The sig-
niﬁcance of the results was taken at the 5% level of signiﬁcance.
The work was carried out in accordance with the Code of
Ethics of the World Medical Association (Declaration of Hel-
sinki) for experiments involving humans. The study protocol
was approved by the review board of both the College of
Medicine and the Institute of Graduate Studies and Research,Table 1 Age and sex among patients with T1DM diabetes and the
Age and sex Cases (n= 60) Contro
No. % No.
Sex
Male 25 41.7 33
Female 35 58.3 27
Age (years)
Min–Max 0.5–18.0 18.0–42.0 Z= 9
Mean ± SD 11.2 ± 3.7 27.2 ± 6.4 P= 0
Disease onset (years)
Min–Max 0.2–17.0 –
Mean ± SD 5.3 ± 3.5 –
X2: Chi-Square; Z: Mann Whitney test; NA: Not applicable.
* Signiﬁcant at P 6 0.05.University of Alexandria, Egypt and a written parental con-
sent and child assent were obtained before the study.4. Results
Table 1 shows that there was a signiﬁcant difference in age
between the two groups (P= 0.0001), to ensure that the
controls were free from T1DM their mean age was
27.2 ± 6.4. There was no signiﬁcant difference in sex between
the two studied groups (P= 0.173). The disease onset range
was 0.2–17 years with a mean of 5.3 ± 3.5 years.
The genotype distributions of IL-18 in Table 2 did not sig-
niﬁcantly differ between T1DM patients and control subjects
(P= 0.641) for the SNP 607 C>A (rs#1946518). On the other
hand, there was a statistically signiﬁcant difference between the
two groups (P= 0.001) for the SNP-137 G>C (rs#187238) at
the genotype level. Table 2 also shows that the genotypic dis-
tributions IL-10 did not signiﬁcantly differ between the two
groups, (P= 0.208) for the SNP 819 C>T (rs#3021097). On
the other hand, there was a statistically signiﬁcant difference
between the two groups (P< 0.0001) for the SNP 1082
G>A (rs#1800896).
Table 2 shows that SNP 49 G>A (rs#231775) in CTLA-4
gene did not signiﬁcantly differ between the patients and con-
trols (P= 0.341).
For vitamin D-receptor polymorphism genotypic distribu-
tions; patients and controls did not signiﬁcantly differ for the
SNP BsmI G>A (rs#1544410), but there was a statistically sig-
niﬁcant difference between the two groups (P= 0.004) for the
SNP Fok1 T>A (rs#2228570).
Table 2 also shows that three SNPs [SNP-2740 C>T
(rs#1217412), SNP-1123 C>G (rs#2488457) and SNP 1858
C>T (rs#2476601)] in PTPN22 gene were genotyped among
the participant groups. It was revealed that the genotypic dis-
tributions did not signiﬁcantly differ between the two groups
(P= 1.0) for the SNP-1858 C>T (rs#2476601). On the other
hand, there was a statistically signiﬁcant difference between the
two groups (P< 0.000) for the SNP-2740 C>T (rs#1217412)
and the SNP-1123 C>G (rs#2488457).
A logistic regression model (Table 3) was adopted for
signiﬁcant results, only vitamin D-receptor SNP Fok1
T>A (rs#2228570), the IL-18 SNP-137 G>C (rs#187238)ir controls.
l (n= 60) Signiﬁcance OR (95% CI)
%
55 X2 = 1.855 –
45 P= 0.173 1.65 (0.8–3.6)
.474
.0001*
Table 3 Logistic regression for SNPs with a signiﬁcant P-value in patients and controls.
B S.E. Wald df Sig. Exp(B) 95.0% CI
Il-10-1082 .443 .313 2.002 1 0.157 1.557 0.843 2.876
VDR.(Fok1) .809 .372 4.737 1 0.030 2.245 1.084 4.650
IL-18-137 .861- .387 4.956 1 0.026 0.423 0.198 0.902
PTPN-1123 .940 .322 8.531 1 0.003 2.561 1.363 4.813
PTPN-2740 .199 .346 0.330 1 0.566 1.220 0.619 2.406
Constant 3.280- .921 12.689 1 0.000 0.038
B= regression co-efﬁcient; S.E. = slandered error; OR = adjusted odd ratio; CL = conﬁdence level.
Table 2 Studied polymorphic sites in some genes among patients with T1DM and their controls.
Gene polymorphism Cases Control X2 P
No. % No. %
IL-18-607
CC 11 18.3 15 25
AA 10 16.7 8 13.3 0.89 0.641
CA 39 65 37 61.7
IL-18-137
GG 15 25 25 41.7
CC 32 53.3 12 20 14.4 0.001*
GC 13 21.7 23 38.3
IL-10-1082
GG 17 28.3 8 13.3
AA 22 36.7 4 6.7 26.3 0.0001*
GA 21 35 48 80
IL-10-819
TT 15 25 22 36.7
CC 13 21.7 7 11.6 3.14 0.208
CTLA-4 49 G>A
AA 6 10 2 3.3
GG 9 15 10 16.7 2.149 0.341
AG 45 75 48 80
Vitamin D-receptor BsmI SNP G>A
GG 8 13.3 4 7.1
AA 13 21.7 11 19.6 1.414 0.493
GA 39 65 41 73.2
Vitamin D-receptor Fok1 T>A
TT 16 26.7 7 11.7
AA 21 35.0 12 20.0 33.7 0.000*
AT 23 38.3 41 68.3
PTPN22 1858 C>T
CC 1 1.9 0 0
TT 12 22.2 12 22.6 MCP= 1.0
CT 41 75.9 41 77.4
PTPN22-1123 G>C
GG 47 78.3 16 26.7
CC 5 8.3 23 38.3 54.900 0.000*
GC 8 13.3 21 35
PTPN22+274 A>G
AA 36 60 20 33.3
GG 10 16.7 14 23.3 19.600 0.000*
AG 14 23.3 26 43.3
X2: Chi-Square.
* Signiﬁcant at P 6 0.05.
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showed the most signiﬁcant difference between patients
and controls.
5. DiscussionThe etiology of human type 1 diabetes is still largely obscure,
but it is recognized that both genetic and environmental fac-
tors are important in deﬁning disease risk. A major focus of
the current research is on the identiﬁcation of putative risk
genes with rarer or structural variants that could contribute
to disease, and it is possible that the regions showing some
evidence of linkage harbor variants that are not common
SNPs well covered by the currently available genotyping
platforms [8].
The aim of this study was to evaluate polymorphic sites in
some genes associated with type 1 diabetes mellitus in a sample
of Egyptian children.
The results showed, in IL-18 gene, that there was a statisti-
cally signiﬁcant difference between the patients and controls
for the SNP-137 G>C (rs# 187238) at the genotype and allele
levels. This result suggests that the genotype CC is a risk factor
for T1DM, Novota et al. [13] in 2005 suggested that the two
variants SNP-607 C>A (rs#1946518) and SNP 137 G>C
(rs#187238) of IL-18 gene are not associated with adult type
1 diabetes or latent autoimmune diabetes in adults (LADA)
susceptibility. Conversely, Dong et al. [14] in 2007, found that
the CC genotype at position-607 in the promoter region of
the IL-18 gene was signiﬁcantly higher (risk factor) in Chinese
Han children with T1DM than that in controls, while the AA
genotype in -607 position could have a protective role for
T1DM.
Present ﬁndings were partially in accordance with those
of Mojtahedi et al. [15] in 2006 who found that there
was no signiﬁcant difference in the distribution of allele
and genotype at positions -137 and -607 of IL-18 gene
between T1DM patients and control subjects without cate-
gorization of patients according to their age in Iranian pop-
ulation. On the other hand, the present ﬁndings regarding
allele and genotype at position -137 of IL-18 gene were
in agreement with those of Massoud et al. [16] in 2009 in
Iranian population and those of Kretowski et al. [17] in
2002 in Polish population. Both of them found that the fre-
quency of GG and CC genotypes at position 137 may be
associated with susceptibility to diabetes.
The genotype GA in IL-10 SNP 1082 G>A (rs#1800896)
(Table 2) was found to be protective from the disease. Studies
conducted in France and Spain did not conﬁrm any signiﬁcant
association of T1DM with different genotypes of IL-10 pro-
moter polymorphisms, in Caucasians population. [18,19]
Mohebbatikaljahi et al. [20] in 2009, showed no link between
T1DM and SNP-819 in IL-10, but previous studies in Turkish
population showed that at the IL-10 SNP-1082 (A/G) poly-
morphic site, the frequencies of GG genotype in patient and
controls showed a signiﬁcant difference. This genotype was
more prevalent in the control group, thus, the G allele may
be a protective allele and genotype ‘GG’ may have a protective
effect against T1DM [20]. It has been proposed that variable
production of Th2 cytokines including IL-10 may inﬂuence
both the degree of b-cell destruction and the age of clinical
onset [21].In this study, the CTLA-4 polymorphisms (SNP 49 G>A
rs#231775), allele and genotypic distributions did not signiﬁ-
cantly differ between the patients and controls, Yanagawa
et al. [22] in 1999, investigated the distribution of a CTLA-4
gene polymorphism in Japanese patients with IDDM and
control subjects, the study did not support an association
between the CTLA-4 gene and IDDM, on the other hand
Ma et al. [23] in 2002, in Han Chinese proved that CTLA-4
49 AA is protective from diabetes mellitus, whereas, CTLA-4
49 G allele (both as homozygotes and as heterozygotes) confers
an increased risk of diabetes mellitus.
The VDR polymorphisms allele and genotypic distributions
did not signiﬁcantly differ in patients and controls for the SNP
BsmI G>A (rs#1544410). On the other hand, there was a sta-
tistically signiﬁcant difference between the two groups for the
SNP -Fok1T>A (rs#2228570), this denotes that TA genotype
may be a risk factor for T1DM in Egyptian children. In the
U.K. populations, Nejentsev et al. [24] in 2004, indicated that
common sequence variation in the VDR gene had no major
effect in T1DM in both loci. Lemos et al. [25] in 2008, sug-
gested that the single nucleotide polymorphisms of the VDR
gene are unlikely to contribute signiﬁcantly to T1DM suscep-
tibility in both loci in the Portuguese population. On the other
hand Wang et al. [26] in 2012, suggested that FokI polymor-
phism in the VDR gene is not associated with T1DM especially
in East Asians, while Bsm I polymorphism in the VDR gene
was associated with T1DM risk, especially in East Asians.
The apparent discrepancies between studies could be a result
of the effect of ethnic differences related to the distribution
of VDR polymorphisms, as well as interactions with other
genetic or environmental factors involved in the pathogenesis
of type 1 diabetes mellitus.
For the three PTPN22 polymorphisms (SNP+2740 C>T
rs#1217412 and SNP-1123 C>G rs#2488457 and SNP 1858
C>T rs#2476601), the distribution analysis of the allelic and
genotypic frequencies revealed that there was no signiﬁcant
difference between patients and controls for the SNP 1858
C>T (rs#2476601). On the other hand, the difference for the
SNP +2740 C>T (rs#1217412) was statistically signiﬁcant.
The result showed that GG and CC genotype may be a risk
factor for T1DM, in addition, there was a statistically signiﬁ-
cant difference between the two groups for the SNP -1123
C>G (rs#2488457) the result showed that AA genotype may
be also a risk factor for T1DM in the Egyptian children.
These results disagree with Tang et al. [27] in 2012, who
proved that T1DM is associated with PTPN22 -1858C/T gene
polymorphism in Chinese population and targeting this pro-
moter polymorphism should be dependent on ethnicity. Xuan
et al. [28] in 2013, in ethnicity-and sex-stratiﬁed analyses,
found similar associations among Caucasians and within Cau-
casian male and female strata. The meta-analysis results sug-
gest that the PTPN22 C1858T polymorphism was associated
with susceptibility to T1DM among the Caucasian population,
and males who carried the 1858T allele were more susceptible
to T1DM than females. Also Lavrikova et al. [29] in 2009,
found that a given polymorphic marker was not statistically
signiﬁcant with T1DM in the transmission disequilibrium test,
while analysis of the distribution of frequencies of alleles and
genotypes showed the association with T1DM. Thus, the poly-
morphic marker C1858T of the PTPN22 gene is associated
with T1DM in Russian patients. On the other hand Santiago
et al. [30] in 2007, proved that the PTPN22 1858T allele is a
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it might play a different role in susceptibility to T1DM accord-
ing to sex in early-onset T1DM patients.
Otherwise Cinek et al. [31] in 2007, proved that in two
different Caucasian populations, the Czechs and the Azeri,
no independent contribution can be detected either of the
-1123 promoter SNP or the +2740 30-UTR SNP, and only
the minor allele at PTPN22 codon 620 contributes to the risk
of autoimmunity.
Liu et al. [32] in 2012, revealed that the 1123 G>C pro-
moter polymorphism of PTPN22 gene, but not the +1858
C>T variant, is associated with LADA in adult Chinese Hans.
Tang et al., [27] in a systematic review and meta-analysis for
(1858C/T, 1123G/C) polymorphisms with type 1 diabetes
mellitus detect no link for PTPN22-1123G/C polymorphism
in Europe, America, and Asia. Kawasaki et al. [33] in 2006,
proved that a regulatory SNP-1123G/C (rs#2488457) was
shown to be weakly associated with T1DM in Japanese and
Koreans.
To conclude, IL-18 SNP-137 G>C (rs#187238), VDR SNP
-Fok1 T>A (rs#2228570), and the SNP -1123 C>G
(rs#2488457) in PTPN22 gene may have an effect on the occur-
rence of T1DM in Egyptian children. Further research includ-
ing large-scale, population-based, case-control studies is
needed.Conﬂict of interest
The authors declare no conﬂict of interest. There is no ﬁnan-
cial and personal relationship with other people or organiza-
tions that could inappropriately inﬂuence this work.
References
[1] Craig M, Hattersley A, Donaghue K. Deﬁnition, epidemiology
and classiﬁcation of diabetes in children and adolescents. Pediatr
Diabetes 2009;10:3–12.
[2] Diagnosis and classiﬁcation of diabetes mellitus. Diabet Care
2008; 31(Suppl. 1): S55–S60.
[3] Kantarova D, Buc M. Genetic susceptibility to type 1 diabetes
mellitus in humans. Physiol Res 2007;56(3):255–66.
[4] Ehehalt S, Dietz K, Willasch AM, Neu A. Prediction model for
the incidence and prevalence of type 1 diabetes in childhood and
adolescence: evidence for a cohort-dependent increase within the
next two decades in Germany. Pediatr Diabet 2012;13(1):15–20.
[5] Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives
on disease pathogenesis and treatment. Lancet 2001;358(9277):
221–9.
[6] Rabinovitch A. Autoimmune diabetes. Sci Med 2000;7(3):18–27.
[7] Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus.
Genes Immun 2002;3(5):235–49.
[8] Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C,
Morahan G, et al. Genetics of type 1 diabetes: what’s next?
Diabetes 2010;59(7):1561–71.
[9] Todd JA. Etiology of type 1 diabetes. Immunity 2010;32(4):
457–67.
[10] Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K,
Plagnol V, et al. Robust associations of four new chromosome
regions from genome-wide analyses of type 1 diabetes. Nat Genet
2007; 39(7): 857–64.
[11] Report of the expert committee on the diagnosis and classiﬁcation
of diabetes mellitus. Diabet Care 2003; 26(Suppl. 1): S5–S20.[12] Sambrook J, Frisch EF, Maniatis T. Molecular cloning: a
laboratory manual. 2nd ed. New York: Cold spring Harbor
laboratory press; 1989.
[13] Novota P, Kolostova K, Pinterova D, Novak J, Treslova L, Andel
M, et al. Interleukin IL-18 gene promoter polymorphisms in
adult patients with type 1 diabetes mellitus and latent autoimmune
diabetes in adults. Immunol Lett 2005;96(2):247–51.
[14] Dong GP1, Yu ZS, Liang L, Zou CC, Fu JF, Wang CL. IL-18
gene promoter 137C/G and 607C/A polymorphisms in Chi-
nese Han children with type 1 diabetes mellitus. Int J Immuno-
genet 2007; 34(2): 75–9.
[15] Mojtahedi Z, Naeimi S, Farjadian S, Omrani GR, Ghaderi A.
Association of IL-18 promoter polymorphisms with predisposi-
tion to Type 1 diabetes. Diabet Med 2006;23(3):235–9.
[16] Massoud A, Bahai NS, Massoud M, Salehi E, Massoud AH,
Vojgani M, et al. IL-18 gene polymorphism in type I diabetic
patients: a case-control study. Tehr Univ Med J 2009;67(1):
20–4.
[17] Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski
M, Puchalski Z, et al. Interleukin-18 promoter polymorphisms in
type 1 diabetes. Diabetes 2002;51(11):3347–9.
[18] Urcelay E, Santiago JL, de la Calle H, Martinez A, Figueredo A,
Fernandez-Arquero M, et al. Interleukin-10 polymorphisms in
Spanish type 1 diabetes patients. Genes Immun 2004;5(4):
306–9.
[19] Reynier F, Cazalis MA, Lecoq A, Paye M, Rosa A, Durand A,
et al. Lack of association of IL-10 promoter gene variants with
type 1 diabetes in a French population. Hum Immunol 2006;
67(4–5): 311–7.
[20] Mohebbatikaljahi H, Menevse S, Yetkin I, Demirci H. Study of
interleukin-10 promoter region polymorphisms (-1082A/G, -
819T/C and -592A/C) in type 1 diabetes mellitus in Turkish
population. J Genet 2009;88(2):245–8.
[21] Ide A, Kawasaki E, Abiru N, Sun F, Takahashi R, Kuwahara H,
et al. Genetic association between interleukin-10 gene promoter
region polymorphisms and type 1 diabetes age-at-onset. Hum
Immunol 2002;63(8):690–5.
[22] Yanagawa T, Maruyama T, Gomi K, Taniyama M, Kasuga A,
Ozawa Y, et al. Lack of association between CTLA-4 gene
polymorphism and IDDM in Japanese subjects. Autoimmunity
1999;29(1):53–6.
[23] Ma Y, Tang X, Chang W, Gao L, Li M, Yan W. CTLA-4 gene A/
G polymorphism associated with diabetes mellitus in Han
Chinese. Chin Med J (Engl) 2002;115(8):1248–50.
[24] Nejentsev S, Cooper JD, Godfrey L, Howson JM, Rance H,
Nutland S, et al. Analysis of the vitamin D receptor gene
sequence variants in type 1 diabetes. Diabetes 2004;53(10):
2709–12.
[25] Lemos MC, Fagulha A, Coutinho E, Gomes L, Bastos M,
Barros L, et al. Lack of association of vitamin D receptor gene
polymorphisms with susceptibility to type 1 diabetes mellitus
in the Portuguese population. Hum Immunol 2008;69(2):
134–8.
[26] Wang Q, Xi B, Reilly KH, Liu M, Fu M. 2012. Quantitative
assessment of the associations between four polymorphisms
(FokI, ApaI, BsmI, TaqI) of vitamin D receptor gene and risk
of diabetes mellitus. Mol Biol Rep 2012; 39(10): 9405–14.
[27] Tang S, Peng W, Wang C, Tang H, Zhang Q. Association of the
PTPN22 gene (+1858C/T, 1123G/C) polymorphisms with type
1 diabetes mellitus: a systematic review and meta-analysis. Diabet
Res Clin Pract 2012; 97(3): 446–52.
[28] Xuan C, Lun LM, Zhao JX, Wang HW, Zhu BZ, Yu S, et al.
PTPN22 gene polymorphism (C1858T) is associated with suscep-
tibility to type 1 diabetes: a meta-analysis of 19,495 cases and
25,341 controls. Ann Hum Genet 2013;77(3):191–203.
[29] Lavrikova E, Nikitin AG, Seregin Iu A, Zil’berman LI, Tsitlidze
NM, Kuraeva TL, et al. Association of the C1858T polymor-
272 A.A. El-Kafoury et al.phism of the PTPN22 gene with type 1 diabetes. Mol Biol (Mosk)
2009; 43(6): 1040–3.
[30] Santiago JL, Martinez A, de la Calle H, Fernandez-Arquero M,
Figueredo MA, de la Concha EG, et al. Susceptibility to type 1
diabetes conferred by the PTPN22 C1858T polymorphism in the
Spanish population. BMC Med Genet 2007;13(8):54.
[31] CinekO,HradskyO, AhmedovG, SlavcevA,Kolouskova S,Kulich
M, et al. No independent role of the1123G>C and+2740A>G
variants in the association of PTPN22 with type 1 diabetes and
juvenile idiopathic arthritis in two Caucasian populations. Diabet
Res Clin Pract 2007;76(2):297–303, Epub 2006 Sep 26.[32] Liu F, Liu J, Zheng TS, Li Q, Wang C, Pan XP, et al. The –
1123G>C variant of PTPN22 gene promoter is associated with
latent autoimmune diabetes in adult Chinese Hans. Cell Biochem
Biophys 2012;62(2):273–9.
[33] Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T,
Nakanishi K, et al. Systematic search for single nucleotide
polymorphisms in a lymphoid tyrosine phosphatase gene
(PTPN22): association between a promoter polymorphism and
type 1 diabetes in Asian populations. Am J Med Genet A
2006;140(6):586–93.
